Affimed to Report Second Quarter 2022 Financial Results & Corporate Update on August 11, 2022
August 04, 2022 06:30 ET
|
Affimed N.V.
HEIDELBERG, Germany, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed Establishes Scientific Advisory Board
June 30, 2022 16:00 ET
|
Affimed N.V.
Independent advisory panel to be made up of distinguished, key opinion leaders with scientific and clinical expertise in innate immunity and oncologyScientific Advisory Board to provide guidance on...
Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
June 10, 2022 10:31 ET
|
Affimed N.V.
AFM28 induced potent, effective, and specific anti-tumor activity against CD123-positive cells irrespective of mutational statusStudy demonstrated specific anti-tumor response even at low levels of...
Affimed Reports First Quarter 2022 Financial Results and Highlights Recent Operational Progress
June 01, 2022 06:30 ET
|
Affimed N.V.
AFM13 monotherapy: Completed enrollment in the REDIRECT study for patients with relapsed or refractory PTCL; on track to report topline data in the fourth quarter of 2022AFM13 combination with NK...
Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
May 26, 2022 17:05 ET
|
Affimed N.V.
Design and rationale of the phase 1/2a open label, multicenter study of the AFM24 monotherapy in patients with advanced EGFR-expressing solid tumorsDesign and rationale of the phase 1/2a study of...
Affimed to Present at the 2022 Jefferies Healthcare Conference
May 26, 2022 06:30 ET
|
Affimed N.V.
HEIDELBERG, Germany, May 26, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed to Report First Quarter 2022 Financial Results & Corporate Update on June 1, 2022
May 24, 2022 06:30 ET
|
Affimed N.V.
HEIDELBERG, Germany, May 24, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed Announces Annual General Meeting of Shareholders
May 24, 2022 06:30 ET
|
Affimed N.V.
HEIDELBERG, Germany, May 24, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity
May 16, 2022 08:00 ET
|
Affimed N.V.
Correlative science data from AFM24-101 clinical study support the rationale to develop AFM24 as monotherapy and in combination therapiesFirst preclinical data set on the combination of AFM28 with...
Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
May 12, 2022 10:31 ET
|
Affimed N.V.
The novel bispecific innate cell engager AFM28 stimulates NK cells to destroy CD123-positive tumor cells via antibody-dependent cellular cytotoxicity.AFM28 induces effective lysis of hematological...